CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0660 (clinicaltrials.gov NCT No: NCT01444742)
Title:Clofarabine plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) who have been Relapsing after, or are Refractory to, Hypomethylator Therapy
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Clofarabine; Cytarabine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if clofarabine when given
in combination with cytarabine can help to control MDS after the disease could
not be controlled with standard therapy. The safety of this treatment will also
be studied.

Clofarabine is designed to interfere with the growth and development of cancer
cells.

Cytarabine is designed to insert itself into DNA (the genetic material of
cells) of cancer cells and stop the DNA from repairing itself.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:Clofarabine
Cytarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults